CLDN18.2

KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.